Orville G. Kolterman

Orville G. Kolterman, M.D. is the chief medical officer of Whole Biome Inc. Prior to that, Dr. Kolterman joined Amylin in 1992 and served as Senior Vice President, Clinical Affairs and Senior Vice President, Regulatory Affairs until 2012, when the company was acquired by AstraZeneca and Bristol-Myers Squibb. Dr. Kolterman was instrumental in the development of Amylin’s first-in-class diabetes medicines, SYMLINⓇ (pramlintide acetate) injection and BYETTAⓇ (exenatide) injection. Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the UC San Diego Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a consultant to the Epidemiology of Diabetes Intervention and Complications Study. Dr. Kolterman received his M.D. from Stanford University School of Medicine.